Dr. Newton-Cheh is a cardiologist seeing advanced heart failure patients and a cardiovascular geneticist conducting research on the root causes of sudden cardiac death and hypertension.
- Centers & Specialties
- Clinical Interests
- Heart failure
- Cardiovascular genetics
- Medical Education
- MD, Columbia University College of Physicians and Surgeons
- MPH, Harvard School of Public Health
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Internal Medicine
- Cardiovascular Disease
- Advanced Heart Failure and Transplant Cardiology
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Patient Age Group
Dr. Newton-Cheh is a cardiologist in the Heart Failure and Transplantation section of the Massachusetts General Hospital Cardiology Division and an Assistant Professor of Medicine at Harvard Medical School. He sees patients with advanced heart failure.
Dr. Newton-Cheh is a faculty member of the Center for Human Genetic Research and the Cardiovascular Research Center, where he co-directs the Human Cardiovascular Genetics Program. He is a complex trait geneticist and cardiovascular epidemiologist. The Newton-Cheh laboratory is focused on the study of hypertension, sudden cardiac death and drug cardiotoxicity. We are leveraging the growth of human genetics to identify DNA sequence variants that contribute to these common diseases, to translate these genetic findings to an improved understanding of human physiology through patient-oriented research and to define the role of genetic variants, alongside other clinical risk factors, in risk prediction at the population level.
- Research Summary
- Dr. Newton-Cheh is faculty member of the Center for Human Genetic Research and the Cardiovascular Research Center, where he co-directs the Human Cardiovascular Genetics Program. Dr. Newton-Cheh is a complex trait geneticist and cardiovascular epidemiologist. The Newton-Cheh laboratory is focused on the study of hypertension, sudden cardiac death and drug cardiotoxicity. We are leveraging the growth of human genetics to improve our understanding of the following outcomes:
QT interval & sudden cardiac death
Sudden cardiac death (SCD) claims 300,000 lives annually in the US and is influenced by genetic factors. Prolongation of the electrocardiographic QT interval is a risk factor for sudden cardiac death and is a life-threatening side effect of medications. We have identified novel genetic variants that contribute to variability of the QT interval and SCD.
Blood pressure & hypertension
Elevated blood pressure (hypertension) affects an estimated 1 billion people world-wide and contributes to the population burden of stroke, heart failure, heart attack, and chronic kidney disease. Until recently the genetic causes of variation in blood pressure in the general population have been poorly defined. We have identified blood biomarkers and common genetic variants that contribute to blood pressure and hypertension.
Two international research studies, both led by investigators affiliated with MGH and the Broad Institute, have uncovered new information about genes that may increase the risk of serious cardiac arrhythmias.
A new report from MGH scientists and colleagues around the world finds that common variants in 28 regions of DNA are associated with blood pressure in human patients. Most of the identified regions were completely unsuspected, and several may lead to a totally new class of hypertension drugs.
Measurement of known biomarkers of cardiovascular disease slightly improves the ability to predict future heart attack or stroke in healthy individuals, but not enough to change preventive therapies.
MGH Hotline 06.12.09 At a time of unprecedented scientific progress and widening public support for clinical and translational research, young and mid-career investigators are faced with challenges of limited funding and competing personal and professional demands that cause many to abandon research careers, noted Janet Hall, MD, of the MGH Reproductive Endocrine Unit, at a May 28 panel discussion during MGH Clinical Research Day.
Scientists from Massachusetts General Hospital (MGH), as part of a major international research collaboration, have associated common variants in eight regions of DNA with blood pressure levels in human patients. Six of the identified regions have not previously been implicated in blood pressure regulation.
A new study has identified several common genetic variants related to a risk factor for sudden cardiac death. The report receiving early online release in the journal Nature Genetics identifies variants in genes, some known and some newly discovered, that influence the QT interval measured on the electrocardiogram (EKG) performed routinely in doctors' offices.
A new study has identified the first common gene variants associated with an increased incidence of hypertension – a significant risk factor for heart attack, stroke and kidney failure.
55 Fruit Street
Boston MA, 02114-2696